ESBL and CRE pathogens

ESBL Pathogens - The Cephalosporin Crushers

• Mechanism: Extended-spectrum β-lactamase enzymes hydrolyze and inactivate most penicillins and cephalosporins (1st, 2nd, and 3rd generations).
• Key Pathogens: 📌 Primarily Klebsiella pneumoniae and Escherichia coli.
• Treatment of Choice: Carbapenems (e.g., Meropenem, Imipenem).
• Lab Detection: Confirmed by showing synergy between a 3rd-gen cephalosporin and a β-lactamase inhibitor (e.g., clavulanic acid).

⭐ ESBL genes are typically located on plasmids, facilitating horizontal gene transfer and rapid spread of resistance between different bacterial species.

CRE Pathogens - Carbapenem's Kryptonite

• Mechanism: Production of carbapenemase enzymes (e.g., KPC, NDM, OXA-48) that hydrolyze carbapenems.
• Genetics: Resistance genes are often carried on mobile plasmids, facilitating rapid horizontal transfer among different bacterial species.
• Key Pathogens: 📌 KEEp resisting Carbapenems: Klebsiella pneumoniae, Enterobacter spp., E. coli.
• Clinical Impact: Cause severe, high-mortality infections (bacteremia, pneumonia, UTIs), particularly in ICU and immunocompromised patients.
• Treatment: Requires newer β-lactam/β-lactamase inhibitor combos (e.g., ceftazidime-avibactam) or last-resort agents like polymyxins.

⭐ The blaKPC gene, a common carbapenemase gene, is frequently located on a mobile Tn4401 transposon within plasmids, contributing to its widespread dissemination.

Lab Diagnosis - Unmasking the Resistance

• ESBL Detection:

  • Screening: Check for resistance to 3rd-gen cephalosporins (e.g., ceftazidime, ceftriaxone).
  • Confirmation: Phenotypic tests use a β-lactamase inhibitor. A ≥5 mm increase in inhibition zone with clavulanate + cephalosporin is positive.

• CRE Detection:

  • Screening: Test for resistance to any carbapenem (e.g., meropenem).
  • Confirmation (Carbapenemase Production):
    • Carba NP Test: Rapid colorimetric assay detects carbapenemase activity.
    • Molecular Tests (PCR): Gold standard. Identifies specific resistance genes like blaKPC, blaNDM, blaOXA-48.

⭐ The Modified Hodge Test (MHT) is no longer recommended by CLSI due to low specificity and being difficult to interpret.

Treatment Strategies - The Counter-Offensive

• ESBL Infections: Carbapenems (Meropenem, Imipenem) are the drugs of choice for systemic infections.

  • For uncomplicated cystitis, oral options like Nitrofurantoin or Fosfomycin may be sufficient.

• CRE Infections: Treatment is guided by the type of carbapenemase produced.

⭐ High-Yield: For Metallo-β-lactamases (MBLs) like NDM, Aztreonam is not hydrolyzed by MBLs but is degraded by co-produced ESBL/AmpC. Adding Ceftazidime-avibactam protects Aztreonam by inhibiting these other β-lactamases, creating a potent combination therapy.

• ESBLs are plasmid-mediated enzymes, primarily in E. coli and Klebsiella, that inactivate most penicillins and cephalosporins.
• Carbapenems are the empiric treatment of choice for serious ESBL infections.
• CRE (Carbapenem-Resistant Enterobacterales) are a major threat due to resistance to carbapenems, often via carbapenemase enzymes (e.g., KPC).
• CRE infections are associated with high mortality and are often acquired in healthcare settings.
• Treatment for CRE is difficult, requiring newer β-lactam/β-lactamase inhibitor combinations or polymyxins.